Yang J, Li R, Shi Y, Jiang S, Liu J. Is serum complement C1q related to major depressive disorder?
Indian J Psychiatry 2020;
62:659-663. [PMID:
33896970 PMCID:
PMC8052891 DOI:
10.4103/psychiatry.indianjpsychiatry_394_19]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 12/25/2019] [Accepted: 04/20/2020] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND
Major depressive disorder (MDD) has a high global incidence. While the pathogenesis of depression remains unknown, accumulating evidence has implicated inflammatory changes.
AIM
The aim of the study is to compare the serum complement C1q levels in patients with MDD and healthy controls.
SETTING AND DESIGN
The design was a case-control study.
MATERIALS AND METHODS
Blood samples were collected from the patients with MDD and healthy controls to assess the serum C1q levels using an immunotransmission turbidimetric method.
STATISTICAL ANALYSIS
Differences in complement C1q levels between patients with MDD and the controls, as well as between sexes among patients with MDD and the controls, were assessed using Mann-Whitney U-test. Spearman correlations were obtained between complement C1q levels and age.
RESULTS
In total, 1016 participants (508 MDD and 508 controls) were recruited. Differences in the sex ratio (male/female among controls, 181/327; and MDD, 178/330) and age (controls, 47.0 ± 14.9 years; MDD, 46.5 ± 16.5 years) were not significant. The C1q level in the patients with MDD was significantly higher than that in the healthy controls (P < 0.05). In the MDD group, C1q level correlated significantly with age.
CONCLUSION
Elevation of the serum complement C1q levels in MDD may support the use of C1q as a potential biomarker for diagnosing depression, but further research is needed.
Collapse